This randomized controlled trial evaluated the efficacy and safety of a home-use device emitting combined blue (420 nm) and red (660 nm) light for treating mild-to-moderate acne vulgaris in Korean patients. Over a 4-week period, participants used the device twice daily, with clinical and histological assessments conducted over 12 weeks.
